Risk assessment of over-the-counter cannabinoid-based cosmetics: Legal and regulatory issues governing the safety of cannabinoid-based cosmetics in the UAE

Sulfoxone
Clinical data
Routes of; administration	Oral
ATC code	J04BA03 (WHO) ;
Pharmacokinetic data
Protein binding	69%
Metabolism	Hepatic
Elimination half-life	3 to 8 hours
Identifiers
	IUPAC name [4-[4-(sulfinomethylamino) phenyl] sulfonylphenyl] aminomethanesulfinic acid;
CAS Number	144-75-2 ;
PubChem CID	8954;
DrugBank	DB01145 ;
ChemSpider	8610 ;
UNII	57OWB0Q221;
KEGG	D02521 ;
ChEMBL	ChEMBL1200580 ;
CompTox Dashboard (EPA)	DTXSID80162594 ;
Chemical and physical data
Formula	C14H16N2Na2O6S3
Molar mass	450.45 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES [Na+].[Na+].[O-]S(=O)CNc1ccc(cc1)S(=O)(=O)c2ccc(NCS([O-])=O)cc2;
	InChI InChI=1S/C14H16N2O6S3.2Na/c17-23(18)9-15-11-1-5-13(6-2-11)25(21,22)14-7-3-12(4-8-14)16-10-24(19)20;;/h1-8,15-16H,9-10H2,(H,17,18)(H,19,20);;/q;2*+1/p-2 ; Key:AZBNFLZFSZDPQF-UHFFFAOYSA-L ;
	(what is this?) (verify)

Sulfoxone or aldesulfone sodium is an anti-leprosy drug.^[1] It is also known as diasone. Sulfoxone sodium was introduced in Japan in 1948.^[2] Ernest Muir introduced it to Western use while serving as superintendent of the Chacachacare Leprosarium on Trinidad in the Caribbean.^[3]

References

^ "Sulfoxone".
^ Ozawa H, Maruyama Y (2002). "[A 50-year history of new drugs in Japan: the developments of antileprosy drugs and their epidemiological aspects]". Yakushigaku Zasshi. 37 (1): 76–83. PMID 12412600.
^ Browne, Stanley George (1974), "Ernest Muir, C.M.G., C.I.E., M.D. (Edin.), F.R.C.S., LL.D. 1880–1974" (PDF), International Journal of Leprosy, vol. 42, no. 4, Bauru: International Leprosy Association, pp. 457–458, PMID 4617724.

[1] "Sulfoxone".

[2] Ozawa H, Maruyama Y (2002). "[A 50-year history of new drugs in Japan: the developments of antileprosy drugs and their epidemiological aspects]". Yakushigaku Zasshi. 37 (1): 76–83. PMID 12412600.

[3] Browne, Stanley George (1974), "Ernest Muir, C.M.G., C.I.E., M.D. (Edin.), F.R.C.S., LL.D. 1880–1974" (PDF), International Journal of Leprosy, vol. 42, no. 4, Bauru: International Leprosy Association, pp. 457–458, PMID 4617724.

[1]

[2]

[3]

Clinical data


Routes of administration	Oral
ATC code	J04BA03 (WHO)
Pharmacokinetic data
Protein binding	69%
Metabolism	Hepatic
Elimination half-life	3 to 8 hours
Identifiers
IUPAC name [4-[4-(sulfinomethylamino) phenyl] sulfonylphenyl] aminomethanesulfinic acid
CAS Number	144-75-2^Y
PubChem CID	8954
DrugBank	DB01145^N
ChemSpider	8610^Y
UNII	57OWB0Q221
KEGG	D02521^Y
ChEMBL	ChEMBL1200580^N
CompTox Dashboard (EPA)	DTXSID80162594
Chemical and physical data
Formula	C₁₄H₁₆N₂Na₂O₆S₃
Molar mass	450.45 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES [Na+].[Na+].[O-]S(=O)CNc1ccc(cc1)S(=O)(=O)c2ccc(NCS([O-])=O)cc2
InChI InChI=1S/C14H16N2O6S3.2Na/c17-23(18)9-15-11-1-5-13(6-2-11)25(21,22)14-7-3-12(4-8-14)16-10-24(19)20;;/h1-8,15-16H,9-10H2,(H,17,18)(H,19,20);;/q;2*+1/p-2^Y Key:AZBNFLZFSZDPQF-UHFFFAOYSA-L^Y
^NY (what is this?) (verify)